A Photoacoustic Contrast Nanoagent with a Distinct Spectral Signature for Ovarian Cancer Management

• DOI: 10.1002/adhm.202202946
• Publication Date: 2022-12-10T09:23:16Z
• Authors: Anna St Lorenz; Abraham S. Moses; Babak Mamnoon; Ananiya A. Demessie; Youngrong Park; Prem Singh; Oleh Taratula; Olena R. Taratula
• Keywords: Spectral signature

Abstract Photoacoustic imaging (PAI) has tremendous potential for improving ovarian cancer detection. However, the lack of effective exogenous contrast agents that can improve PAI diagnosis accuracy significantly limits this application. This study presents a novel nanoagent with specific spectral signature be easily distinguished from endogenous chromophores in tissue, allowing high‐contrast tumor visualization. Constructed as 40 nm biocompatible polymeric nanoparticle loaded two naphthalocyanine dyes, agent is capable efficient accumulation after intravenous injection. The developed displays well‐separated photoacoustic peaks comparable PA intensities near‐infrared (NIR) region at 770 and 860 nm, which remain unaffected tissue following systemic delivery. In vivo experiments mice subcutaneous intraperitoneal xenografts validate allows accurate unmixing signal sensitive noninvasive diagnosis. addition, selectively eradicate single dose photothermal therapy by elevating intratumoral temperature to ≈49 °C upon exposure NIR light within 700–900 range.